
Agustín Toll
Research group
- Melanoma: imaging, genetics and immunology Accredited researcher (R3A)
Featured publications
-
Risk Factors and Rate of Recurrence after Mohs Surgery in Basal Cell and Squamous Cell Carcinomas: A Nationwide Prospective Cohort (REGESMOHS, Spanish Registry of Mohs Surgery)
Authors:Reference: Acta Dermato-Venereologica 2021. -
Mohs surgery: a long-term, nationwide prospective cohort to describe recurrence rate and risk factors (REGESMOHS, Spanish Registry of Mohs Surgery)
Authors:Reference: Journal Of The European Academy Of Dermatology And Venereology 2021. -
PATTERNS OF INCIDENTAL PERINEURAL INVASION AND PROGNOSIS IN CUTANEOUS SQUAMOUS CELL CARCINOMA: A MULTICENTER, RETROSPECTIVE COHORT STUDY
Authors:Reference: Journal Of The American Academy Of Dermatology 2021. -
Erythematous papules on the penis as first manifestation of metastatic prostate adenocarcinoma
Authors:Reference: Dermatology Online Journal 2021. -
Estimated Effect of COVID-19 Lockdown on Skin Tumor Size and Survival: An Exponential Growth Model
Authors:Reference: Actas Dermo-Sifiliograficas 2020. -
Molecular characterisation of oncogenic urothelial mosaic mutations in patients with extensive keratinocytic epidermal naevi
Authors:Reference: Journal Of Medical Genetics 2020. -
Identification of differentially expressed genes in actinic keratosis samples treated with ingenol mebutate gel
Authors:Reference: Plos One 2020. -
State of the art of Mohs surgery for rare cutaneous tumors in the Spanish Registry of Mohs Surgery (REGESMOHS)
Authors:Reference: International Journal Of Dermatology 2019. -
Metastatic Cutaneous Squamous Cell Carcinomas
Authors:Reference: 2017. -
Multifaceted role of TREX2 in the skin defense against UV-induced skin carcinogenesis.
Authors:Reference: Oncotarget 2015.
Featured Projects
-
Development and Validation of a Gene Expression assay to Predict the Risk of Recurrence Disease in Cutaneous Squamous Cell Carcinoma
Funder: Castle BiosciencesDuration: 31/08/2021 - 23/03/2022 -
Estudio de fase 2 de REGN2810, un anticuerpo monoclonal totalmente humano contra la proteína de muerte celular programada-1 (PD-1), en pacientes con carcinoma epidermoide cutáneo avanzado
Funder: Regeneron PharmaceuticalsDuration: 05/11/2019 -
Red de cáncer cutáneo no melanoma en Cataluña
Principal investigator: Agustín TollDuration: 13/03/2019 -
Regulación epigenética de la función inflamatoria del componente epitelial en la progresión metastática del carcinoma escamoso cutáneo (CEC)
Principal investigator: María Inmaculada Hernández MuñozFunder: Instituto de Salud Carlos IIIDuration: 01/01/2016 - 31/12/2018 -
Estudio del perfil genómico y de expresión en carcinomas escamosos cutáneos invasivos e intraepiteliales
Principal investigator: Agustin Toll AbelloDuration: 01/01/2011 - 31/12/2013